Reducing LDL-C with Non-Statin Therapies
Lipid specialists Drs. Lynne Braun and Michael Miller discuss the importance of LDL cholesterol management for prevention and management of atherosclerotic cardiovascular disease (ASCVD). The role of non-statin therapies including emerging evidence with PCSK9 inhibition on major CV outcomes is presented in this dynamic presentation.
Upon completion of this continuing education course, participants will be able to:
- Describe how to interpret cholesterol guidelines and identify patient populations with unmet needs on statin therapy.
- Explain best practices for reducing LDL-C with non-statin therapies.
Supported by an independent educational grant from Amgen, Inc.
- Lynne Braun, PhD, CNP, CLS, FAHA, FAAN, FPCNA
- Michael Miller, MD, FACC, FAHA